New monthly pill shows potential as pre-exposure prophylaxis HIV drug candidate

New monthly pill shows potential as pre-exposure prophylaxis HIV drug candidate

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond, et al from Merck & Co., Inc., Rahway, NJ, USA, published in PLOS Biology. HIV pre-exposure prophylaxis (PrEP) is a key part of reducing the number of new HIV infections. The most common oral PrEP therapies, consisting of once-daily pills, are highly effective at protecting people from acquiring HIV, but they …